newsfilter
← Latest News
GlobeNewswire·

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026

  • Eisai and Biogen announced that five years of continuous lecanemab treatment (LEQEMBI) for early Alzheimer's disease reduced the relative risk of progression to the next disease stage by 36% compared to Alzheimer's Disease Neuroimaging Initiative (ADNI) data.
  • Among patients with low tau accumulation treated for five years, 62% showed improvement in cognitive function & activities of daily living (CDR-SB), while 66% showed no decline.
  • The Clarity AD study found that the clinical benefit of lecanemab continued to accrue over time, with mean CDR-SB differences from baseline worsening by only 1.00, 1.78, & 2.05 points at years three, four, & five respectively compared to natural history decline.
  • In the low tau population, 55% of patients showed no decline on the ADAS-Cog14 scale, & 52% showed improvement, while 69% showed no decline & 62% showed improvement on the ADCS MCI-ADL scale for daily living activities.
  • Lecanemab reduced the relative risk of progressing from early Alzheimer's to moderate or severe dementia by 49% compared to ADNI data, with only 31% of treated patients progressing versus 48.7% in the natural history cohort.
  • No new safety findings were observed during the five-year treatment period, with amyloid-related imaging abnormalities with edema/effusion (ARIA-E) incidence decreasing from 13.5% in the first 12 months to 0.6% in the fifth year.
  • The study included 1,795 patients, with 95% of core study completers entering the long-term extension & 351 patients receiving five years of continuous treatment.
  • Lecanemab is an anti-amyloid beta protofibril antibody that targets both soluble protofibrils & insoluble amyloid plaques, & is currently approved in 53 countries with additional subcutaneous formulations approved in the U.S., China, & Japan as of late 2026.
Company
Biogen Inc.
Keywords
Nasdaq:BIIB, Biogen Inc.